Navigation Links
Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
Date:10/1/2007

Study Data Show Patients with Moderate to Severe Psoriasis Who Responded to Anti-IL-12/23 ABT-874 after 12 Weeks of Treatment, Maintained Response at

24 Weeks

BUENOS AIRES, Argentina, Oct. 1 /PRNewswire-FirstCall/ -- Results from an extension to a Phase II study evaluating the effectiveness of Abbott's (NYSE: ABT) investigational anti-IL-12/23 antibody ABT-874 showed that a majority of patients who initially responded to treatment maintained a high level of response following discontinuation of therapy. In the study, patients who achieved 75 percent improvement in psoriasis signs and symptoms (PASI 75) at 12 weeks stopped receiving ABT-874. At 24 weeks, more than two- thirds of these patients maintained at least 50 percent improvement (PASI 50). The Phase II study, conducted in patients with moderate to severe psoriasis, will be presented at the World Congress of Dermatology in Buenos Aires.

Phase II results presented earlier this year at the Society for Investigative Dermatology (SID) Meeting showed ABT-874 reduced psoriasis symptoms significantly in the majority of patients treated. At 12 weeks, at least 90 percent of patients with moderate to severe psoriasis achieved 75 percent improvement in psoriasis signs and symptoms in all but the lowest dosing groups receiving ABT-874, versus 3 percent of patients receiving placebo. Also, more than half of patients achieved 90 percent improvement, in the same four of five ABT-874 dosing groups, versus 0 percent of those receiving placebo.

"ABT-874 represents a novel approach to treating psoriasis, targeting a part of the inflammatory response that is not addressed by any therapy available today," said Alan Menter, MD, Chair,
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
6. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
7. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
8. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
9. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
10. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
11. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Aug. 28, 2014 /PRNewswire-iReach/ -- Gateway Analytical announced ... 9 th Annual Global Pharma Manufacturing Summit ... 8-9 th . The Global Pharma Manufacturing Summit ... small molecule and biologic pharmaceutical manufacturing. The conference ... today,s manufacturers face, such as the increasing pressure ...
(Date:8/28/2014)... , Aug. 28, 2014  Robotic surgery is ... media, both for the promise of improved outcomes ... quick deployment of surgical robots and market pressures ... facilities to evaluate their robotic surgery training programs ... team.    ECRI Institute ( www.ecri.org ...
(Date:8/28/2014)... THOUSAND OAKS, Calif. , Aug. 28, 2014 /PRNewswire/ ... the submission of a Biologics License Application (BLA) to ... seeking approval for the treatment of high cholesterol. Evolocumab ... proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that ... (LDL-C), or "bad" cholesterol, from the blood. 1 ...
Breaking Medicine Technology:Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9
... Mass. , July 26 The Exergen ... nationwide that stock the Exergen TemporalScanner™, according to data ... of all types of thermometers, including national brands and ... found Exergen came out on top. Exergen,s retail unit ...
... , NEWARK, Del. and GRONINGEN, Netherlands ... a leading full-service GLP/GCP-compliant contract research organization providing testing ... announced the completion of its acquisition of Xendo Drug ... .  XDD, a European contract research organization (CRO), will ...
Cached Medicine Technology:Exergen TemporalScanner Thermometer Best Selling Brand at Retailers 2QPS Announces the Acquisition of Xendo Drug Development 2QPS Announces the Acquisition of Xendo Drug Development 3QPS Announces the Acquisition of Xendo Drug Development 4
(Date:8/28/2014)... Mateo, CA (PRWEB) August 28, 2014 ... that the MRI Technology program is re-accredited for the ... of Magnetic Resonance Imaging Technologists (ARMRIT). , “We ... We are constantly improving our program to make sure ... is a lot of interest in MRI field nowadays ...
(Date:8/28/2014)... Did they fall from trees and learn to flap their ... ground and pump their "arms" to get aloft? , The ... a new University of California, Berkeley, study provides a new ... maneuver in midair, a talent that could have helped their ... , The study looked at how baby birds, in this ...
(Date:8/28/2014)... Data from the American Hospital Association’s 2013 Annual ... a basic electronic health record (EHR) system, more advanced ... challenge. , This data is featured in an ... , and is co-authored by Peter Kralovec, executive director ... as Chantal Worzala, director for policy at the AHA. ...
(Date:8/28/2014)... Ariz. Aug. 28, 2014 In 2012, ... million in grants for two groundbreaking brain cancer ... (TGen). One of those projects has officially received ... San Francisco, which means patient enrollment for the ... project, "Genomics Enabled Medicine in Glioblastoma Trial," TGen ...
(Date:8/28/2014)... CORAL GABLES, Fla (Aug. 26, 2014)-- Cigarette smoking ... the Centers for Disease Control and Protection. It,s ... order to overcome this addiction, many people resort ... literature review study by researchers at the University ... nicotine found in cigarette substitutes could be harmful ...
Breaking Medicine News(10 mins):Health News:Gurnick Academy’s MRI Program Is Re-Accredited by ARMRIT for the 5 Years 2Health News:Flapping baby birds give clues to origin of flight 2Health News:Flapping baby birds give clues to origin of flight 3Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 2Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 3Health News:TGen receives approval for patient enrollment in brain cancer clinical trial 2Health News:Are cigarette substitutes a safe alternative? It depends on user habits 2Health News:Are cigarette substitutes a safe alternative? It depends on user habits 3
... In a research paper presented at the 113th Annual ... that it is possible to regulate the incidence of ... the computer to stay connected with people.,The data regarding ... of the latest wave of an ongoing longitudinal study ...
... was extracted from the Herb Black Cohosh [An Indian herb], ... [HRT]. Doctors say herb used by American Indians for ... for women going through menopause. As synthetic HRT use is ... , ,Professor John Eden from Sydney’s Royal Hospital for ...
... hours for treatment for heart attacks, may be more ... blood flow, said a research // findings in the ... blood flow to an organ or tissue) with either ... coronary intervention (PCI; procedures such as angioplasty in which ...
... how neurons fire in a part of the brain ... of schizophrenia and Alzheimer's disease. // , ,A ... nervous system has been the focus of the research. ... them where they're supposed to go. In adult mice, ...
... disorders like rheumatoid arthritis may be reduced by ... carrots and sweetcorn. //, ,Vitamin C and ... in brightly-coloured fruit and veg, may act as ... damage and inflammation. ,The levels of intake ...
... Researchers from University of Michigan had identified a protein ... sensori-neural hearing loss or AISNHL.//, ,In the August ... Neck Surgery, researchers reports results from a study of ... Pennsylvania and Indiana, and 20 people with normal hearing. ...
Cached Medicine News:Health News:Heart Attack Patients Reaching Hospital During Off-Hours Have Increased Risk Of Death 2Health News:Learning process to be regulated by altering brain protein 2
... Introducing the new PRONEB® ULTRA compressor. ... treatment time while delivering more medication to ... PARI LC PLUS® or PARI LC STAR® ... are optimized for inhalation and retention into ...
... Compressed Air., ,Allied Healthcares Timeter® PCS 414 ... other air compressors that you may wonder if ... PCS 414 features a durable, mar-resistant steel case ... unit weighs only 26.5 pounds. The PCS 414 ...
... DC powered compressor nebulizer system available. ... to take nebulizer treatments away from ... the included AC power adapter or ... The integral reusable jet nebulizer kit ...
The 45 PSI SuperSportNeb provides superior performance that translates to shorter treatment times. Like the SportNeb, it is constructed with die-cast aluminum compressor components for consistent rel...
Medicine Products: